Event on
The value of CRP point-of-care testing in the fight against antimicrobial resistance
Présentations
-
Prof. Nicholas Francis
(UK)
ChairSafe reduction of antibiotics for acute exacerbations of chronic obstructive pulmonary disease using CRP point-of-care testing: The findings of the PACE Study.
-
Prof. Rogier Hopstaken
(The Netherlands)
SpeakerReduction of antibiotic prescribing at primary care: Evidence of the established role of CRP point-of-care testing.
-
Prof. Ivan Gentile
(Italy)
SpeakerThe fight against antimicrobial resistance in Italy.
Les points de vues et opinions présentés n’engagent que les orateurs. Le contenu de ce webcast est destiné à des fins informatives / éducatives uniquement.
CONTEXTE
Join our panel of experts from across Europe to learn about the value of C-reactive protein (CRP) point-of-care testing (POCT) to help fight antimicrobial resistance and as an aid to help avoid the misuse of antibiotics. 90% of respiratory tract infections (RTIs) are viral and therefore antibiotics have no clinical benefit. And yet RTIs are one of the most common reasons for unnecessary antibiotic prescribing [1]. The webinar will analyse studies and present front-line experience on the value of CRP POCT told through the eyes of internationally acclaimed healthcare professionals and academics from the UK, the Netherlands and Italy.
Les points de vues et opinions présentés n’engagent que les orateurs. Le contenu de ce webcast est destiné à des fins informatives / éducatives uniquement.
- ↑ CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Update 27. Oct 2020. Downloaded June 2021. https://stacks.cdc.gov/view/cdc/89980
© 2024 Abbott. Tous les droits sont réservés. Toutes les marques commerciales référencées sont des marques commerciales du groupe de sociétés Abbott ou de leurs propriétaires respectifs. COL-00000